Sangamo Therapeutics Inc. share price logo

Sangamo Therapeutics Inc.

NASDAQ: SGMO

$0.07

-0.10

(-58.05%)

as on

Bell Icon

This instrument is not available for trading on the INDmoney app on 23 Jun 2026

Sangamo Therapeutics Inc. Stock Performance

as on June 24, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.06
    $0.12
    downward going graph

    14.29%

    Downside

    71.43%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.06
    $0.77
    downward going graph

    9.00%

    Downside

    994.29%

    Upside

    downward going graph

Sangamo Therapeutics Inc. share price movements today

Previous Close
$0.17
Open
$0.08
Volume
46.5M
Day's Low - High
$0.06 - $0.12
52 Week Low - High
$0.06 - $0.77

Sangamo Therapeutics Inc. Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Sangamo Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Sangamo Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

Sangamo Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sangamo Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Sangamo Therapeutics Inc. image
Sangamo Therapeutics Inc.
BUY$-NANA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$39.9B478.19%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$40.3B82.45%75.812.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$126.4B163.31%29.5935.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$65.5B12.1%15.2529.65%0.5700000000000001%

Analyst Recommendation on Sangamo Therapeutics Inc. Stock

Based on 15 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 15 analysts, 66.67% of analysts recommend a 'BUY' rating for Sangamo Therapeutics Inc.. Average target price of $1.5

Sangamo Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Sangamo Therapeutics Inc..

What analysts predicted

95.33%UPSIDE

Target Price

$1.5

Current Price

$0.07

Analyzed by

15 Analysts

Target

$1.50

Sangamo Therapeutics Inc. target price $1.5, a slight upside of 95.33% compared to current price of $0.07. According to 15 analysts rating.

Sangamo Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
2
0
0
49
7
6
18
0
14
1
Gross Profit
2
0
0
49
7
6
18
0
14
1
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-60
-49
-36
10
-23
-30
-19
-34
-37
-30
Net Profit Margin
-2952.74%
-10205.61%
-10148.31%
21.60%
-309.84%
-475.33%
-109.18%
-6012.05%
-263.00%
-2149.45%

Sangamo Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
19
36
84
102
118
110
111
176
57
39
Gross Profit
19
36
84
102
118
110
111
176
57
31
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-71
-54
-68
-75
-121
-178
-192
-257
-97
-122
Net Profit Margin
-369.58%
-149.23%
-80.91%
-74.02%
-102.48%
-161.06%
-172.76%
-146.30%
-169.45%
-310.81%

Global Institutional Holdings in Sangamo Therapeutics Inc.

Funds
Holdings
Two Sigma Advisers, LLC
1.05%
Northern Trust Corp
0.18%
Wasatch Advisors LP
0.34%
UBS Group AG
0.62%
GSA Capital Partners LLP
0.74%
See all

Sangamo Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 23 June

    Tue, 11:16 PM

    -

    Sangamo Therapeutics files for Chapter 11 bankruptcy, seeking to sell assets through court-supervised process.

Insights on Sangamo Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -37.41M → -30.99M (in $), with an average increase of 20.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, SGMO stock has moved up by 11.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, REVOLUTION Medicines Inc has given 473.9% return, outperforming this stock by 563.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, REVOLUTION Medicines Inc has given 268.4% return, outperforming this stock by 339.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.22M → 1.44M (in $), with an average decrease of 89.9% per quarter

About Sangamo Therapeutics Inc.

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
OrganisationSangamo Therapeutics Inc.
E-voting on sharesClick here to vote

FAQs

What is Sangamo Therapeutics Inc. share price today?

Sangamo Therapeutics Inc. share price today is $0.07 as on at the close of the market. Sangamo Therapeutics Inc. share today touched a day high of $0.12 and a low of $0.06.

What is the 52 week high and 52 week low for Sangamo Therapeutics Inc. share?

Sangamo Therapeutics Inc. share touched a 52 week high of $0.77 on and a 52 week low of $0.06 on . Sangamo Therapeutics Inc. stock price today i.e. is closed at $0.07,which is 90.86% down from its 52 week high and 9.89% up from its 52 week low.

How to invest in Sangamo Therapeutics Inc. Stock (SGMO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sangamo Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sangamo Therapeutics Inc. Shares that will get you 21.4286 shares as per Sangamo Therapeutics Inc. share price of $0.07 per share as on June 24, 2026 at 1:29 am IST.

What is the minimum amount required to buy Sangamo Therapeutics Inc. Stock (SGMO) from India?

Indian investors can start investing in Sangamo Therapeutics Inc. (SGMO) shares with as little as ₹95.2 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.00 in Sangamo Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Sangamo Therapeutics Inc. share’s latest price of $0.07 as on June 24, 2026 at 1:29 am IST, you will get 142.8571 shares of Sangamo Therapeutics Inc.. Learn more about fractional shares .